4578.T
Otsuka Holdings Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 12,240.00
+0.41%Sep 2, 2026, 09:17 UTC
Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.
Source:Aug 15, 2026, 02:00 UTC
Otsuka Holdings is considering entering the European market with its Pocari Sweat sports drink and expanding sales regions in the US, as part of its overseas business expansion.
Source:Aug 2, 2026, 18:30 UTC
The U.S. Food and Drug Administration approved Otsuka's new ADHD drug Simtriyo (centanafadine) for adults and children aged 6 and older on July 24, 2026.
Source:Jul 15, 2026, 20:30 UTC
Otsuka Holdings introduced a storage battery system at its Kushiro plant in Hokkaido, in collaboration with Enaris and TES Engineering, marking the group's first such installation.
Source:Jun 4, 2026, 19:59 UTC
Otsuka reported Phase 3 trial results for its drug Voyxact in patients with IgA nephropathy.
Source: